Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG registries

01 Pubblicazione su rivista
Antonelli Manila, Hoffman Lindsey M., Veldhuijzen van Zanten Sophie E. M., Colditz Niclas, Baugh Joshua, Chaney Brooklyn, Hoffmann Marion, Lane Adam, Fuller Christine, Miles Lili, Hawkins Cynthia, Bartels Ute, Bouffet Eric, Goldman Stewart, Leary Sarah, Foreman Nicholas K., Packer Roger, Warren Katherine E., Broniscer Alberto, Kieran Mark W., Minturn Jane, Comito Melanie, Broxson Emmett, Shih Chie-Schin, Khatua Soumen, Chintagumpala Murali, Sophie Carret Anne, Yanez Escorza Nancy, Hassall Timothy, Ziegler David S., Gottardo Nicholas, Dholaria Hetal, Doughman Renee, Benesch Martin, Drissi Rachid, Nazarian Javad, Jabado Nada, Boddaert Nathalie, Varlet Pascale, Giraud G´eraldine, Castel David, Puget Stephanie, Jones Chris, Hulleman Esther, Modena Piergiorgio, Giagnacovo Marzia, Antonelli Manila, Pietsch Torsten, Gielen Gerrit H., Jones David T. W., Sturm Dominik, Pfister Stefan M., Gerber Nicolas U., Grotzer Michael A., Pfaff Elke, von Bueren Andr´e O., Hargrave Darren, Solanki Guirish A., Jadrijevic Cvrlje Filip, Kaspers Gertjan J. L., Vandertop William P., Grill Jacques, Bailey Simon, Biassoni Veronica, Massimino Maura, Calmon Raphael, Sanchez Esther, Bison Brigitte, Warmuth-Metz Monika, Leach James, Jones Blaise, van Vuurden Dannis G., Kramm Christof M., Fouladi Maryam
ISSN: 0732-183X

Purpose Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with a median survival of < 1 year. The International and European Society for Pediatric Oncology DIPG Registries collaborated to compare clinical, radiologic, and histomolecular characteristics between short-term survivors (STSs) and long-term survivors (LTSs). Materials and Methods Data abstracted from registry databases included patients from North America, Australia, Germany, Austria, Switzerland, the Netherlands, Italy, France, the United Kingdom, and Croatia. Results Among 1,130 pediatric and young adults with radiographically confirmed DIPG, 122 (11%) were excluded. Of the 1,008 remaining patients, 101 (10%) were LTSs (survival ≥ 2 years). Median survival time was 11 months (interquartile range, 7.5 to 16 months), and 1-, 2-, 3-, 4-, and 5-year survival rates were 42.3% (95% CI, 38.1% to 44.1%), 9.6% (95% CI, 7.8% to 11.3%), 4.3% (95% CI, 3.2% to 5.8%), 3.2% (95% CI, 2.4% to 4.6%), and 2.2% (95% CI, 1.4% to 3.4%), respectively. LTSs, compared with STSs, more commonly presented at age < 3 or > 10 years (11% v 3% and 33% v 23%, respectively; P < .001) and with longer symptom duration ( P < .001). STSs, compared with LTSs, more commonly presented with cranial nerve palsy (83% v 73%, respectively; P = .008), ring enhancement (38% v 23%, respectively; P = .007), necrosis (42% v 26%, respectively; P = .009), and extrapontine extension (92% v 86%, respectively; P = .04). LTSs more commonly received systemic therapy at diagnosis (88% v 75% for STSs; P = .005). Biopsies and autopsies were performed in 299 patients (30%) and 77 patients (10%), respectively; 181 tumors (48%) were molecularly characterized. LTSs were more likely to harbor a HIST1H3B mutation (odds ratio, 1.28; 95% CI, 1.1 to 1.5; P = .002). Conclusion We report clinical, radiologic, and molecular factors that correlate with survival in children and young adults with DIPG, which are important for risk stratification in future clinical trials.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma